GlassScriptPhysician profile
Sujata Sitaula
NPI 1548678261
$4,944.84
in general payments reported to CMS, 2019-2025
27 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $154 · 2022: $1,357 · 2023: $1,405 · 2024: $885 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,256 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.04 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,409.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,169.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Absolute Pro |
| Lilly USA, LLC | $533.98 | 2022-2025 | Jardiance, Mounjaro, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $235.88 | 2022-2024 | Farxiga |
| Insulet Corporation | $189.41 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $153.01 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $137.50 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $125.86 | 2024-2025 | |
| Mannkind Corporation | $122.92 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.47 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $116.92 | 2022-2025 | Repatha, Evenity |
| Medtronic, INC. | $112.23 | 2022-2025 | Minimed 780g |
| Abbvie INC. | $90.85 | 2022-2024 | Creon, Linzess |
| Ibsa Pharma INC. | $75.60 | 2022-2024 | Tirosint, Licart, Licart |
| Tandem Diabetes Care, INC. | $52.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $45.01 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ipsen Biopharmaceuticals, INC | $37.25 | 2019 | |
| Corcept Therapeutics | $37.03 | 2023 | Korlym |
| Averitas Pharma INC. | $27.03 | 2025 | Qutenza |
| Dexcom, INC. | $24.42 | 2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $21.05 | 2023 | Strensiq |
| Radius Health, INC. | $20.31 | 2022 | |
| Cequr Corporation | $19.52 | 2025 | Cequr Simplicity |
| Lifescan, INC. | $19.30 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $18.81 | 2024 | |
| Madrigal Pharmaceuticals | $17.11 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujata Sitaula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.